Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. 44
Introduction 56
Prostate cancer is known to be a notoriously heterogeneous disease and the genetic basis for 57 this interpatient heterogeneity is poorly understood 1, 2 . The ongoing development of new therapies for 58 metastatic prostate cancer that target molecularly defined subgroups further increases the need for 59 accurate patient classification and stratification [3] [4] [5] . Analysis of whole-exome sequencing data of 60 metastatic prostate cancer tumors revealed that 65% of patients had actionable targets in non-61 androgen receptor related pathways, including PI3K, Wnt and DNA repair 6 . Several targeted agents 62 involved in these pathways, including mTOR/AKT pathway inhibitors 7 and PARP inhibitors 8 , are 63 currently in various phases of development and the first clinical trials show promising results. 64 Therefore, patients with metastatic prostate cancer could benefit from better stratification to select the 65 most appropriate therapeutic option. More extensive analysis using whole-genome sequencing 66 (WGS) based classification of tumors may be useful to improve selection of patients for different 67 targeted therapies. The comprehensive nature of WGS has many advantages including the detection 68 of mutational patterns, as proven by the successful treatment of patients with high tumor mutational 69 burden with immune checkpoint blockade therapy [9] [10] [11] [12] . Moreover, WGS unlike exome sequencing, can 70 detect structural variants and aberrations in non-coding regions, both important features of prostate 71 cancer. 72
73
The stratification of prostate cancer patients, based on differences in the mutational 74 landscape of their tumors, has mainly focused on mutually-exclusive mutations, copy number 75 alterations or distinct patterns in RNA-sequencing caused by the abundant TMPRSS2-ERG fusion, 76 which is recurrent in 50% of primary prostate tumors 6,13-18 . More recently, WGS of metastatic prostate 77 cancer tumors demonstrated that structural variants arise from specific alterations such as CDK12 -/-78 and BRCA2 -/genotypes and are strongly associated with genome-wide events such as large tandem 79 duplications or small genomic deletions, respectively [19] [20] [21] [22] [23] . Advances in WGS and interpretation have 80 revealed rearrangement signatures in breast cancer relating to disease stage, homologous 81 recombination deficiency (HRD) and BRCA1/BRCA2 defects based on size and type of structural 82 variant 22, 24 . Thus, WGS enables the identification of patterns of DNA aberrations (i.e. genomic scars) 83 that may profoundly improve classification of tumors that share a common etiology, if performed in a 84 sufficiently powered dataset. 85 4 86
In this study, we analyzed the WGS data obtained from 197 metastatic castration-resistant 87 prostate cancer (mCRPC) patients. We describe the complete genomic landscape of mCRPC, 88
including tumor specific single and multi-nucleotide variants (SNVs and MNVs), small insertions and 89 deletions (InDels), copy number alterations (CNAs), mutational signatures, kataegis, chromothripsis 90 and structural variants (SVs). Next, we compared the mutational frequency of the detected driver 91 genes and genomic subgroups with an unmatched WGS cohort of primary prostate cancer (n = 210), 92 consisting of exclusively of Gleason score 6-7 tumors 15, 25 . We investigated the presence of possible 93 driver genes by analyzing genes with enriched (non-synonymous) mutational burdens and recurrent 94 or high-level copy number alterations 26, 27 . By utilizing various basic genomic features reflecting 95 genomic instability and employing unsupervised clustering, we were able to define eight distinct 96 genomic subgroups of mCRPC patients. We combined our genomic findings with AR, FOXA1 and 97
H3K27me ChIP-seq data and confirmed that important regulators of AR-mediated signaling are 98 located in non-coding regions with open chromatin and highlight the central role of AR signaling in 99 tumor progression. 100
Results 101

Characteristics of the mCRPC cohort and sequencing approach 102
We analyzed fresh-frozen metastatic tumor samples and matched blood samples from 197 103 castration-resistant prostate cancer (CRPC) patients using WGS generating to date the largest WGS 104 dataset for mCRPC ( Figure 1a ). Clinical details on biopsy site, age and previous treatments of the 105 included patients are described in Figure 1b -c and Supplementary table 2. WGS data was sequenced 106 to a mean coverage of 104X in tumor tissues and 38X in peripheral blood (Supplementary figure 1a) . 107
The median estimated tumor cell purity using in silico analysis of our WGS data was 62% (range: 16-108 96%; Supplementary figure 1b). Tumor cell purity correlated weakly with the frequency of called SNVs 109 (Spearman correlation; rho = 0.2; p = 0.005), InDels (Spearman correlation; rho = 0.35; p < 0.001), 110 MNVs (Spearman correlation; rho = 0.25; p < 0.001) and structural variants (Spearman correlation; 111 rho = 0.22; p = 0.002; Supplementary figure 1c). 112
113
Landscape of mutational and structural variants in mCRPC 114
The median tumor mutational burden (TMB) at the genomic level (SNVs and InDels per Mbp) 115 was 2.7 in our mCRPC cohort, including 14 patients with high TMB (> 10). We found a median of 116 6,621 single-nucleotide variants (SNVs; IQR: 5,048-9,109), 1,008 small insertions and deletions 117 (InDels; IQR: 739-1,364), 55 multi-nucleotide variants (MNVs; IQR: 34-86) and 224 SVs (IQR: 149-118 370) per patient (Supplementary figure 2a-c). We observed a highly complex genomic landscape 119 consisting of multiple driver mutations and structural variants in our cohort. 120
We confirmed that known driver genes of prostate cancer were enriched for non-synonymous 121 mutations ( Figure 2 and Supplementary figure 2e) 13,15,28 . In total, we detected 11 genes enriched with 122 non-synonymous mutations: TP53, AR, FOXA1, SPOP, PTEN, ZMYM3, CDK12, ZFP36L2, PIK3CA 123 and APC. ATM was mutated in 11 samples, but after multiple-testing correction appeared not to be 124
enriched. 125
Our copy number analysis revealed distinct amplified genomic regions including 8q and Xq 126 and deleted regions including 8p, 10q, 13q and 17p (Supplementary figure 2d ). Well-known prostate 127 cancer driver genes 8, 16 , such as AR, PTEN, TP53 and RB1, are located in these regions. In addition 128 to large-scale chromosomal copy number alterations, we could identify narrow genomic regions with 129 6 recurrent copy number alterations across samples which could reveal important prostate cancer driver 130 genes ( Supplementary table 3) . 131 TMPRSS2-ERG gene fusions were the most common fusions in our cohort (n = 84 out of 132 197; 42.6%) and were the majority of ETS family fusions (n = 84 out of 95; 88.4%; Figure 2 and 133 Supplementary figure 3). This is comparable to primary prostate cancer, where ETS fusions are found 134 in approximately 50% of tumors 13, 15 . The predominant break point was located upstream of the 135 second exon of ERG, which preserves its ETS-domain in the resulting fusion gene. 136
In 42 patients (21.3%), we observed regional hypermutation (kataegis; Figure 2 and 137 Supplementary figure 4). In addition, we did not observe novel mutational signatures specific for 138 metastatic disease or possible pre-treatment histories (Supplementary figure 5) 29 . 139
To further investigate whether our description of the genome-wide mutational burden and 140 observed alterations in drivers and/or subtype-specific genes in mCRPC were metastatic specific, we 141 compared our data against an unmatched WGS cohort of primary prostate cancer (n = 210) 15,25 , 142 consisting of Gleason score 6-7 disease. Comparison of the median genome-wide TMB (SNVs and 143 InDels per Mbp) revealed that the TMB was roughly 3.8 times higher in mCRPC ( Figure 3a ) and the 144 frequency of structural variants was also higher ( Figure 3b ) between disease stages, increasing as 145 disease progresses. Analysis on selected driver and subtype-specific genes showed that the 146 mutational frequency of several genes (AR, TP53, MYC, ZMYM3, PTEN, PTPRD, ZFP36L2, 147 ADAM15, MARCOD2, BRIP1, APC, KMT2C, CCAR2, NKX3-1, C8orf58 and RYBP) was significantly 148 altered (q ≤ 0.05) between the primary and metastatic cohorts (Figure 3c-e). All genes for which we 149 observed significant differences in mutational frequency, based on coding mutations, were enriched in 150 mCRPC ( Figure 3d ). We did not identify genomic features that were specific for the metastatic setting, 151 beyond androgen deprivation therapy-specific aberrations revolving AR (no aberrations in hormone-152 sensitive setting versus 137 aberrations in castration-resistant setting). We cannot exclude from these 153 data that matched sample analysis or larger scale analysis could reveal such aberrations. 154
We next determined whether previous treatments affect the mutational landscape. Using 155 treatment history information, we grouped prior secondary anti-hormonal therapy, taxane-based 156 chemotherapy and systemic radionucleotide therapy into different groups (Supplementary figure 6 ).
160
The role of the AR-pathway in mCRPC 161
Focusing on the AR-pathway revealed that aberrant AR signaling occurred in 80% of our 162 patients. In 57.3% of patients both AR and the AR-enhancer (~66.13 Mb on chromosome X; located 163 about 629 kbp upstream of the AR gene 20 ) were affected ( Figure 4a ). In an additional 6.6% and 164 14.7% of tumors only AR gene alterations or AR-enhancer amplification occurred, respectively. The 165 percentage of mCRPC patients with the exclusive AR-enhancer amplification (29 out of 197; 14.7%) 166 versus exclusively AR-locus amplification (13 out of 197; 6.6%) is similar to previous observations 167 which showed 21 out of 94 CRPC patients (10.3%) with exclusively AR-enhancer amplification versus 168 4 out of 94 CRPC patients (4.3%) with exclusively AR-locus amplification 20 . Thus, concurrent 169 amplification of the AR gene and the AR-enhancer was not necessarily of equal magnitude, which 170 resulted in differences in copy number enrichment of these loci ( Figure 4b ). 171
To date no AR ChIP-seq data has been reported in human mCRPC samples and evidence of 172 increased functional activity of the amplified enhancer thus far is based on cell line models 30 . To 173 resolve this, we performed AR ChIP-seq on two selected mCRPC patient samples with AR-enhancer 174 amplification based on WGS data. As controls we used two prostate cancer cell-lines (LNCaP and 175 VCaP) and three independent primary prostate cancer samples that did not harbor copy number 176 alterations at this locus (Supplementary figure 7) 31 . We observed active enhancer regions (H3K27ac) 177 in the castration-resistant setting, co-occupied by AR and FOXA1, at the amplified AR-enhancer, 178 which is substantially stronger when compared to the hormone-sensitive primary prostate cancer 179 samples without somatic amplifications (Figure 4c and Supplementary figure 7 ). Furthermore, a 180 recurrent focal amplification in a non-coding region was observed at 8q24.21 near PCAT1. This locus 181 bears similar epigenetic characteristics to the AR-enhancer with regard to H3K27ac and, to a lesser 182 extent, binding of AR and/or FOXA1 in the mCRPC setting ( Figure 4d and Supplementary figure 7) . 183
184
WGS-based stratification defines genomic subgroups in mCRPC 185
Our comprehensive WGS data and large sample size enabled us to perform unsupervised 186 clustering on several WGS characteristics to identify genomic scars that can define subgroups of 187 mCRPC patients. We clustered our genomic data using the total number of SVs, relative frequency of 188 SV events (translocations, inversions, insertions, tandem duplications and deletions), genome-wide 189 8 TMB encompassing SNV, InDels and MNV, and tumor ploidy. Prior to clustering, we subdivided 190 tandem duplications and deletions into two major categories based on the respective genomic size of 191 the aberration (smaller and larger than 100 kbp) since previous studies revealed distinctions based on 192 similar thresholds for these structural variants in relation to specific mutated genes [19] [20] [21] 32 Remarkably, seven out of twenty-two patients did not have 213 a biallelic BRCA2 inactivation. However, four of these patients showed at least one (deleterious) 214 aberration in other BRCAness-related genes (Figure 6b ) 35 . Cluster F was enriched for chromothripsis 215 events, however we could not reproduce a previous finding suggesting chromothripsis was associated 216 with inversions and p53 inactivation in prostate cancer 21 . Apart from the chromothripsis events, no 217 clear gene aberration was associated with this cluster (Figure 6b ). In the remaining patients, there 218 were no distinct genomic signatures or biologic rationale for patient clustering (cluster C, E, G, H). In 219 9 cluster C, conjoint aberrations of BRCA1 and TP53 were observed in one patient with a high HR-220 deficiency prediction score (CHORD), which is known to lead to a small tandem duplication 221 phenotype (< 100 kbp) 32 . Two other patients within cluster C displayed a weak CHORD scoring 222 associated with HR-deficiency, however no additional definitive evidence was found for a BRCA1 223 loss-of-function mutation within these patients. 224
In addition to our unsupervised clustering approach, we clustered our samples using the 225 clustering scheme proposed by TCGA (Supplementary figure 12a ), which defines seven clusters 226 based on coding mutations and copy number aberrations in SPOP, FOXA1, IDH1 and ETS family 227 gene fusions (and overexpression) per promiscuous partner (ERG, ETV1, ETV4 and FLI1) 13 . 228
Unfortunately, we currently lack matched mRNA-sequencing data in our cohort and therefore cannot 229 observe overexpression of fused ETS family members which restricted us to only characterize the 230 genomic breaks of these promiscuous partners. Without incorporation of ETS family overexpression, 231 this proposed clustering scheme categorizes 61% of mCRPC into these seven groups versus 68% of 232 the original cohort containing primary prostate cancer described by TCGA (Supplementary figure  233 12b) 13 . There was no significant correlation between the TCGA clustering scheme and our defined 234 genomic subtypes such as MSI, BRCAness or CDK12 -/-. In addition, we did not detect statistical 235 enrichment or depletion (q ≤ 0.05) between these supervised clusters and additional mutated genes, 236 kataegis and chromothripsis, only the known enrichment of homozygous CHD1 deletions in the 237 SPOP-cluster was observed 13 . 238 239 Performing unsupervised clustering and principal component analysis on the primary prostate 240 cancer and metastatic cohorts revealed no striking primary-only genomic subgroup nor did we detect 241 the presence of the mCRPC-derived genomic subgroups in the primary prostate cancer cohort 242 (Supplementary figure 14) . This could reflect the absence of CDK12 mutations and the presence of 243 only three sporadic BRCA2 mutated samples (1%) in the primary prostate cancer cohort. 244 Furthermore, only one sample (1%) with MSI-like and high TMB (> 10), respectively, was observed in 245 the primary cancer cohort. Indeed, there is a striking difference in the mutational load between both 246 disease settings. 247
Discussion 248
We performed WGS of metastatic tumor biopsies and matched normal blood obtained from 249 197 patients with mCRPC to provide an overview of the genomic landscape of mCRPC. The size of 250 our cohort enables classification of patients into distinct disease subgroups using unsupervised 251 clustering. Our data suggest that classification of patients using genomic events, as detected by 252 WGS, improves patient stratification, specifically for clinically actionable subgroups such as BRCA 253 deficient and MSI patients. Furthermore, we confirm the central role of AR signaling in mCRPC that 254 mediates its effect through regulators located in non-coding regions and the apparent difference in 255 primary versus metastatic prostate cancers. 256
257
The classification of patients using WGS has the advantage of being, in theory, more precise 258 in determining genomically defined subgroups in prostate cancer compared to analyses using 259 targeted panels consisting of a limited number of genes, or exome sequencing. The identification of 260 subgroups based on predominant phenotypic characteristics encompassing genomic signatures may 261 be clinically relevant and our clustering analysis refines patient classification. In cluster A, we 262 observed a high TMB which has been associated in other tumor types with a high sensitivity to 263 immune check-point inhibitors 9, 11, 12 In addition, PCAT1 is a long non-coding RNA which is known to be upregulated in prostate 289 cancer and negatively regulates BRCA2 expression while positively affecting MYC expression 38,39 . 290
Combining our WGS approach with AR, FOXA1 and H3K27ac ChIP-seq data, we identify non-coding 291 regions affecting both AR itself, and possibly MYC, through AR-enhancer amplification as a potential 292 mechanism contributing to castration resistance. 293
294
A potential pitfall of our clustering analysis is the selection of features used; for this we made 295 a number of assumptions based on the literature and distribution of the structural variants within our 296 cohort 19-21,32 . As the input features and weights for clustering analysis are inherent to the clustering 297 outcome, we performed additional clustering analyses using various combinations of these features 298 and applied alternative approaches but did not detect striking differences compared to the current 299 approach. Another potential pitfall of the employed hierarchical clustering scheme is that patients are 300 only attributed to a single cluster. An example of this can be seen in cluster A where a patient is 301 grouped based on its predominant genotype (MSI) and associated mutations in MMR-related genes 302 (MLH1, POLE, POLD3 and BLM), but this sample also displays an increased number of structural 303 variants and increased ploidy status and harbors a pathogenic BRCA2 mutation. However, it is 304 missing the characteristic number of genomic deletions (< 100 kbp) and BRCA mutational signature 305 associated with BRCA2 -/samples that define cluster D. Despite these pitfalls we conclude that 306 unbiased clustering contributes towards improved classification of patients. 307 12 308
The CPCT-02 study was designed to examine the correlation of genomic data with treatment 309 outcome after biopsy at varying stages of disease. Our cohort contains patients with highly variable 310 pre-treatment history and since the treatments for mCRPC patients nowadays significantly impacts 311 overall survival, the prognosis of patients differs greatly. Therefore, correlation between genomic data 312 and clinical endpoints, such as survival is inherently flawed due to the very heterogeneous nature of 313 the patient population. Moreover, our analysis comparing primary and metastatic samples shows a 314 significant increase in the number of genomic aberrations with advancing disease, meaning that the 315 difference in timing of the biopsies may bias the prognostic value of the data. In future studies we plan 316 to gather all known clinically defined prognostic information and determine whether the genomic 317 subtypes increase the ability to predict outcome. Unfortunately, some clinical parameters with 318 prognostic importance such as ethnicity will not be available due to ethical regulations. Moreover, we 319 will increase the sample size, in order to correlate genomic features to clinical parameters to better 320 determine whether the subtypes we identified are stable over time. Therefore, we are currently unable 321 to present meaningful correlations between clinical endpoints and the clusters we identified. 
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Figure legends
No biopsy taken n = 24
Fresh-frozen biopsy and blood control taken n = 314
Successful biopsy (TC% ≥30%) n = 218
Failed biopsy (TC% < 30%) n = 96
No WGS due to insufficient tumor DNA quantity n = 1 WGS biopsy (114x) and blood control (38x) n = 217 non-mCRPC 
